Navigation Links
Omeros and BlueCrest Announce $20 Million Debt Facility
Date:9/24/2008

SEATTLE and CHICAGO, Sept. 24 /PRNewswire/ -- Omeros Corporation, a Seattle-based biopharmaceutical company, today announced the establishment of a $20 million debt facility with BlueCrest Capital Finance. The facility consists of a $5 million term loan drawn by Omeros at closing and the right, subject to certain conditions, to access up to the remaining $15 million. Other terms were not disclosed.

"This credit facility provides us with increased financial flexibility as we continue to expand our clinical programs and advance our deep preclinical pipeline," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "The BlueCrest team has a strong track record, and agreed to terms that meet our business objectives."

"Our decision to make a significant investment in Omeros was driven by the quality of its management team, program portfolio, intellectual property and business strategy," said Chris York, Managing Director of BlueCrest Capital Finance. "We are excited to be working with Omeros and look forward to the Company's future achievements."

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and central nervous system disorders. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.

About BlueCrest Capital Finance

BlueCrest Capital Finance, L.P., a US based commercial finance company, provides debt financing solutions to development stage companies in a broad range of industry sectors including IT, Communications, Hardware, Software, Semi-Conductor, Electronics, Energy, Medical Device and Life Science. The team, which has been together continuously since 1998, pursues debt transactions in the $1-25 million range and has consummated approximately 800 transactions with total commitments in excess of $1.8 billion.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Omeros Appoints David A. Mann to its Board of Directors
3. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
4. Chromos announces timing of closing of Arrangement
5. TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
6. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
7. AHIC Successor, Inc. Announces Board of Directors
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
10. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
11. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK Business ... US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants module ... and biologic sealants used in surgical applications. BioMedGPS estimates the market will grow ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):